Literature DB >> 23561879

Substrain-specific differences in survival and osteonecrosis incidence in a mouse model.

Jitesh D Kawedia1, Laura Janke, Amy J Funk, Laura B Ramsey, Chengcheng Liu, David Jenkins, Kelli L Boyd, Mary V Relling.   

Abstract

We previously reported strain-specific susceptibility to dexamethasone-induced osteonecrosis in mice. Here we report that BALB/cJ and BALB/cAnNHsd mice display substrain-specific differences in dexamethasone-induced adverse effects. As compared with BALB/cJ mice, BALB/cAnNHsd weighed more (16.6 g compared with 13.7 g) at the beginning of dexamethasone administration on postnatal day 28 and fewer died during the dexamethasone regimen (10% compared with 50%). Although the 2 substrains had similar plasma concentrations of dexamethasone, BALB/cJ mice were more susceptible to developing dexamethasone-induced osteonecrosis. A higher dose of dexamethasone (8 mg/L) throughout the treatment period compared with a lower dose (8 mg/L loading dose during week 1 followed by 4 mg/L for the remainder of the treatment period) and earlier start of treatment (postnatal day 24 compared with postnatal day 28) was required to induce osteonecrosis with a similar frequency in BALB/cAnNHsd mice as in BALB/cJ mice. Our results show, for the first time, substrain-specific differences in the development of osteonecrosis in mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23561879      PMCID: PMC3527750     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  13 in total

1.  Variations in LPS responsiveness among different mouse substrains of C3H lineage and their congenic derivative sublines.

Authors:  O J Silvia; N Urosevic
Journal:  Immunogenetics       Date:  1999-12       Impact factor: 2.846

2.  Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice.

Authors:  R J Ralph; M P Paulus; M A Geyer
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

3.  The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources.

Authors:  Melanie L Graham; Jody L Janecek; Jessica A Kittredge; Bernhard J Hering; Henk-Jan Schuurman
Journal:  Comp Med       Date:  2011-08       Impact factor: 0.982

4.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Jitesh D Kawedia; Sue C Kaste; Deqing Pei; John C Panetta; Xiangjun Cai; Cheng Cheng; Geoffrey Neale; Scott C Howard; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

5.  Differential cocaine sensitivity between two closely related substrains of C57BL mice.

Authors:  K K Henricks; L L Miner; R J Marley
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

6.  BALB/c substrain differences in susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  S M Nicholson; J D Peterson; S D Miller; K Wang; M C Dal Canto; R W Melvold
Journal:  J Neuroimmunol       Date:  1994-06       Impact factor: 3.478

7.  A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday.

Authors:  Lei Yang; Kelli Boyd; Sue C Kaste; Landry Kamdem Kamdem; Richard J Rahija; Mary V Relling
Journal:  J Orthop Res       Date:  2009-02       Impact factor: 3.494

8.  Mouse strain differences in immunosuppression by opioids in vitro.

Authors:  T K Eisenstein; J J Meissler; T J Rogers; E B Geller; M W Adler
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

9.  Nicotine-induced tolerance and receptor changes in four mouse strains.

Authors:  M J Marks; E Romm; D K Gaffney; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

10.  Experimental allergic orchitis in mice. V. Resistance to actively induced disease in BALB/cJ substrain mice is mediated by CD4+ T cells.

Authors:  C Teuscher; W F Hickey; R Korngold
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

View more
  13 in total

1.  Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model.

Authors:  Laura B Ramsey; Laura J Janke; Mathew J Edick; Cheng Cheng; Richard T Williams; Charles J Sherr; William E Evans; Mary V Relling
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

2.  Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.

Authors:  Emily R Finch; Laura J Janke; Colton A Smith; Seth E Karol; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Ching-Hon Pui; Joshua Wolf; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2019-02-13       Impact factor: 3.167

3.  Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.

Authors:  Emily R Finch; Laura J Janke; Lie Li; Monique A Payton; David A Jenkins; Kristine R Crews; Mary V Relling; Seth E Karol
Journal:  Pediatr Blood Cancer       Date:  2021-12-05       Impact factor: 3.167

4.  Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis.

Authors:  Laura J Janke; Chengcheng Liu; Peter Vogel; Jitesh Kawedia; Kelli L Boyd; Amy J Funk; Mary V Relling
Journal:  Am J Pathol       Date:  2013-05-11       Impact factor: 4.307

5.  Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model.

Authors:  Chengcheng Liu; Laura J Janke; Jitesh D Kawedia; Laura B Ramsey; Xiangjun Cai; Leonard A Mattano; Kelli L Boyd; Amy J Funk; Mary V Relling
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

6.  Development of Neurological Mouse Model for Toxoplasmosis Using Toxoplasma gondii Isolated from Chicken in Kenya.

Authors:  John Mokua Mose; David Muchina Kamau; John Maina Kagira; Naomi Maina; Maina Ngotho; Adele Njuguna; Simon Muturi Karanja
Journal:  Patholog Res Int       Date:  2017-05-24

7.  Prevalence of glucocorticoid induced osteonecrosis in the mouse is not affected by treatments that maintain bone vascularity.

Authors:  Nancy E Lane; Geetha Mohan; Wei Yao; Kie Shidara; Yu-An Evan Lay; Jia Junjing; Alanna Dubrovsky; Donald B Kimmel
Journal:  Bone Rep       Date:  2018-11-03

8.  Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.

Authors:  Laura B Ramsey; Laura J Janke; Monique A Payton; Xiangjun Cai; Steven W Paugh; Seth E Karol; Landry Kamdem Kamdem; Cheng Cheng; Richard T Williams; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

9.  A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice.

Authors:  Xue Yang; Chi Liu; Masayuki Fujino; Ji Yang; Xiao-Kang Li; Hejian Zou
Journal:  FEBS Open Bio       Date:  2017-08-16       Impact factor: 2.693

10.  Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.

Authors:  Seth E Karol; Laura J Janke; John C Panetta; Laura B Ramsey; Xiangjun Cai; Monique A Payton; David A Jenkins; William E Evans; Mary V Relling
Journal:  PLoS One       Date:  2019-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.